Abstract PO-137: Comparative transcriptomic analysis of prostate cancer from African American and Caucasian American men by Gleason score and race

Author(s):  
Muthana Al Abo ◽  
Wen-Chi Foo ◽  
Daniel J. George ◽  
Steven R. Patierno ◽  
Jennifer A. Freedman
2015 ◽  
Vol 2015 ◽  
pp. 1-6 ◽  
Author(s):  
R. Renee Reams ◽  
Jacqueline Jones-Triche ◽  
Owen T. M. Chan ◽  
Brenda Y. Hernandez ◽  
Karam F. A. Soliman ◽  
...  

In a previously published study, we showed that expression of theABCD3gene increased with increasing metastatic potential in a panel of prostate cancer cell lines derived from African American and Caucasian American men. Given importance of identifying biomarker(s) that can distinguish indolent versus aggressive prostate tumors, we conducted an immunohistochemical analysis ofABCD3expression Caucasian and African American prostate tumors.ABCD3expression in each patient population was compared with clinicopathologic characteristics, Gleason score, and age.ABCD3expression increased with increasing Gleason score (P=0.0094), age (P=0.0014), and pathology grade (P=0.0007) in Caucasian patients. Interestingly, in the AA patients,ABCD3expression highly increased to the same degree in both low and high Gleason score tumors. Similarly,ABCD3expression was elevated to the same degree in BPH derived from AA. Our findings demonstrate that increasedABCD3expression correlates with Gleason Score in CA prostate tumors. However, in AA prostate tumors,ABCD3expression was higher and was sustained in both low Gleason and high Gleason AA tumors. While the functional role ofABCD3in prostate cancer is not completely elucidated, this gene warrants further study as a potential biomarker for aggressive prostate.


The Prostate ◽  
2018 ◽  
Vol 78 (11) ◽  
pp. 801-811 ◽  
Author(s):  
Desta A. Beyene ◽  
Tammey J. Naab ◽  
Norma F. Kanarek ◽  
Victor Apprey ◽  
Ashwini Esnakula ◽  
...  

2010 ◽  
Vol 8 (1) ◽  
pp. 70 ◽  
Author(s):  
Amy E Rose ◽  
Jaya M Satagopan ◽  
Carole Oddoux ◽  
Qin Zhou ◽  
Ruliang Xu ◽  
...  

Cancer ◽  
2013 ◽  
Vol 119 (12) ◽  
pp. 2282-2290 ◽  
Author(s):  
Shellie D. Ellis ◽  
Bonny Blackard ◽  
William R. Carpenter ◽  
Merle Mishel ◽  
Ronald C. Chen ◽  
...  

2018 ◽  
Vol 36 (6_suppl) ◽  
pp. 41-41
Author(s):  
Daniel Canter ◽  
Julia E. Reid ◽  
Maria Latsis ◽  
Margaret Variano ◽  
Shams Halat ◽  
...  

41 Background: Prostate cancer (PC) is the most common male malignancy. Prior data has suggested that African American (AA) men present with more aggressive disease relative to men of other ancestries. Here, we examined the effects of ancestry on clinical and molecular measures of disease aggressiveness as well as pathologic outcomes in men treated with radical prostatectomy (RP) for localized PC. Methods: Data was collected from patients undergoing RP at the Ochsner Clinic from 2006 to 2011. Formalin−fixed paraffin embedded biopsy tissue was analyzed for the RNA expression of 31 cell cycle progression (CCP) genes and 15 housekeeping genes to obtain a CCP score (a validated molecular measure of PC aggressiveness). Cancer of the Prostate Risk Assessment (CAPRA) scores were also determined based on clinicopathologic features at the time of diagnosis. Clinical (Gleason score, tumor stage, CAPRA score) and molecular (CCP score) measures of disease aggressiveness were compared based on ancestry (AA versus non−AA). Cox proportional hazards models were used to test association of ancestry to biochemical recurrence (BCR) and progression to metastatic disease. Fisher’s exact and Wilcoxon rank sum tests were used to compare ancestries. Results: A total of 384 patients were treated with RP, including 133 (34.8%) AA men. At the time of diagnosis, the median age was 62 years (interquartile range (IQR) 56, 66) and PSA was 5.4 ng/mL (IQR 4.2, 7.6). When compared by ancestry, there were no significant differences in biopsy Gleason score (p = 0.26), clinical stage (p = 0.27), CAPRA score (p = 0.58), or CCP score (p = 0.87). In addition, there was no significant difference in the risk of BCR between ancestries (p = 0.55). Only non−AA men progressed to metastatic disease within the ten years of follow−up. Conclusions: Contrary to prior reports, these data appears to indicate that men of AA ancestry do not necessarily present with or develop a more biologically aggressive form of PC. Although these data represents only one institution’s experience, it contains a highly robust AA population compared to prior reports. Further research is required to account for the discrepancy in the previously published literature.


Sign in / Sign up

Export Citation Format

Share Document